Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822465 · ClinicalTrials.gov registry record
Pathobiomes in Gut of Critically Ill Patients
A clinical trial of Pseudomonas Aeruginosa, sponsored by University of Chicago.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06822465 is a study of Pseudomonas Aeruginosa that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 100 participants, roughly in line with the 95-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06822465, a study of Pseudomonas Aeruginosa, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb to multi-organ failure and septicemia secondary to an invasive nosocomial infection. The sequelae of shock, hypoxia, and parental nutrition result in injury to the intestinal mucosa, changes in gut permeability, and failure of intestinal defense mechanisms. These conditions put patients at risk for infection and multiple organ failure secondary to the translocation of enteric bacteria, initiating a systemic release of inflammatory mediators-a process that has been termed gut-derived sepsis. Intestinal P. aeruginosa senses host factors released during stress and responds by activating its virulence gene machinery. As such, the presence of a highly activating intestinal milieu serves to induce virulence in strains of P. aeruginosa and this correlates to the severity of a patient's illness. While the host-pathogen interaction is a dynamic process, the study expects that as a patient's illness worsens or resolves over time, the "virulence-activating" properties of their intestinal milieu will change accordingly. This study will conduct a prospective observational trial in a population of critically ill patients at the Universtiy of Chicago Medical Center. This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The study also plans to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
Conditions Studied
Interventions
- OTHER P. aeruginosa using in vitro and in vivo assays
Study Locations (1)
Illinois
- The University of Chicago - Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06822465
The ClinicalTrials.gov registry entry for NCT06822465 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 95-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pseudomonas Aeruginosa appearing as the primary indexed condition, and to 1 intervention - of which P. aeruginosa using in vitro and in vivo assays is the first listed.
NCT06822465 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06822465 about?
NCT06822465 is a clinical study titled "Pathobiomes in Gut of Critically Ill Patients". Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb...
What is the current status of trial NCT06822465?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-12-19. Estimated completion is 2029-12.
What conditions does trial NCT06822465 study?
This clinical trial studies the following conditions: Pseudomonas Aeruginosa.
What interventions are being tested in trial NCT06822465?
The interventions under investigation include: P. aeruginosa using in vitro and in vivo assays (OTHER).
Who is sponsoring clinical trial NCT06822465?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06822465 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pseudomonas Aeruginosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PMT for MDRO Decolonization
RECRUITING · Phase 2
-
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
RECRUITING · Phase 1
-
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
COMPLETED
-
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.